BSI Partnering with Pharnext on $14.2M Initiative to Develop Biomarkers and Therapeutics for AD

Funded by the French innovation agency OSEO, the collaboration calls for the companies to develop a prototype blood-based protein biomarker test for Alzheimer's disease as well as a therapeutic for the disease and a companion diagnostic.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.